Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial

IMPORTANCE: The effect of continuing vs withdrawing treatment with semaglutide, a glucagon-like peptide 1 receptor agonist, on weight loss maintenance in people with overweight or obesity is unknown. OBJECTIVE: To compare continued once-weekly treatment with subcutaneous semaglutide, 2.4 mg, with sw...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:JAMA
Main Authors: Rubino, Domenica, Abrahamsson, Niclas, Davies, Melanie, Hesse, Dan, Greenway, Frank L., Jensen, Camilla, Lingvay, Ildiko, Mosenzon, Ofri, Rosenstock, Julio, Rubio, Miguel A., Rudofsky, Gottfried, Tadayon, Sayeh, Wadden, Thomas A., Dicker, Dror
פורמט: Artigo
שפה:Inglês
יצא לאור: American Medical Association 2021
נושאים:
Original Investigation
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7988425/
https://ncbi.nlm.nih.gov/pubmed/33755728
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2021.3224
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים